Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that sales of therapies to treat hepatocellular carcinoma (HCC) in China will nearly triple from $53 million in 2009 to $144 million in 2014. Fueling this growth will be greater access to medical care, a growing drug-treated patient population and a rising number of higher-income HCC patients requesting the more-efficacious and costly Western brands of targeted agents such as Bayer's Nexavar.

The new Emerging Markets report entitled Liver Cancer in China finds that, based on positive results obtained in medical practice and ongoing clinical studies, the use of targeted therapies to treat HCC in China will continue to increase as physicians become more confident using these agents. Chinese physicians report that Nexavar, Shandong Simcere Medgenn's Endostar and Chengdu Huasheng's Li Ka Ting are the main targeted therapies used for HCC in China. Additionally, by 2014, another targeted agent--brivanib (Bristol-Myers Squibb's BMS-582664)--is expected to be formally approved for HCC in China, but its uptake will be modest and will most likely occur initially in the second-line setting.

The report also finds that sales of agents manufactured by multinational corporations (MNCs) will account for more than two-thirds of total HCC drugs sales in China in 2014.

"Liver cancer drugs manufactured by MNCs, which accounted for 54 percent of total sales in China in 2009, will increase to 68 percent of total sales in 2014," said Decision Resources Analyst Jing Wu. "The key reason for this growth is the increasing uptake of expensive MNC brands of targeted therapies in urban regions of China - the uptake of these targeted therapies will offset the declining market share of conventional branded chemotherapies manufactured by MNCs."

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.      For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-993-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-993-2597,
ccomfort@dresources.com

Summary Paper Now Available From Decision Resources Entitled Genzyme as Acquisition Target: Opportunities and Risks in its Business and Key Niche Markets

View Now